Pricing Under The Spotlight As Novo Files Next-Generation Insulins
Executive Summary
Novo Nordisk AS says it won’t seek the highest price it believes its next-generation insulins, the ultra-long-acting Degludec and Degludec Plus, could command on the basis of health economic data alone.
You may also be interested in...
Degludec Advisory Committee Is Another De Facto Delay For Novo
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
More Insulin Innovation To Come, Says Novo CEO Sorensen
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices
Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country